MRKR MARKER THERAPEUTICS INC Investments/Divestments 8-K Filing 2023 - Press Release Marker Therapeutics, Inc. reported non-clinical data on their lead multiTAA-specific T cell product candidate for AML treatment and announced a $2 million grant from NIH SBIR program.Get access to all SEC 8-K filings of the MARKER THERAPEUTICS INC